AUAutolus Therapeutics plc AUTL · NASDAQ
$1.52 -4.11% (-$0.07)
- Market cap
- $420.5M
- Enterprise value
- $332.6M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 3.6x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -57.6%
- Gross margin
- 15.7%
- Net margin
- -238.6%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 2.14
- Free float
- 90.4%
About the company
Autolus Therapeutics plc (AUTL) is a biotechnology company focused on developing immunotherapeutic drugs for cancer treatment. Utilizing advanced technologies in the field of gene engineering and cell therapy, Autolus Therapeutics aims to develop innovative therapies that selectively target cancer cells and minimize the side effects of traditional treatment methods. The company focuses on developing personalized treatment approaches that take into account individual genetic characteristics of patients. With its commitment to research and development, Autolus Therapeutics offers hope for new, effective therapeutic options in the fight against cancer. Autolus Therapeutics plc (AUTL) shares could be suitable for investors looking for investments in biotechnology with an emphasis on innovative cancer treatment.
Sector
Healthcare
Industry
Biotechnology
CEO
Christian Martin Itin
Employees
752
Headquarters
London
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 130% a year over the last 3 years.
- What speaks for it: Analysts expect revenue to grow by 98% this fiscal year.
- What to watch: It missed profit estimates 4 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $171.4M against $83.5M.
- What to watch: It passes only 3 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number